Compare Kimberly Clark Corp (KMB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Recursion Pharmaceuticals Inc — how do they compare? Kimberly Clark Corp trades at $97.96 (market cap $32.51B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: Kimberly Clark Corp is far larger — about 15.2× Recursion Pharmaceuticals Inc's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KMB | RXRX | |
|---|---|---|
Market Cap | $32.51B | $2.14B |
Volume | 6,139,913 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $6.79 |
52-Week Low | $93.05 | $2.84 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $38.07B | $1.66B |
Dividend Yield | 5.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $98.02, up 1.6% on the day, showing modest recovery from recent weakness. The stock faces bearish technical signals with support at $96 and resistance at $98. Fundamentally, the company maintains strong profitability with 11.79% net margins and consistent dividend payments, though revenue declined to $16.45B in 2025. Recent executive transitions and the pending Kenvue acquisition create both uncertainty and strategic opportunity.
KMB offers a compelling dividend yield above 5% with 54 consecutive years of increases, but faces execution risks from the Kenvue integration. Analyst consensus targets $117.25 (19% upside) with mixed sentiment (32% buy, 58% hold). The stock presents value for income investors but requires careful monitoring of acquisition progress and cash flow sustainability.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
